Q4 2025 Incyte Corp Earnings Call Transcript

Feb 10, 2026 / 01:00 PM GMT

Release Date Price: €84.16 (-8.00%)

Transcript 10-K8-K

Key Points

Positve

Incyte Corp (INCY) exceeded expectations in total sales, JACfi sales, and core business sales excluding JACfi in 2025.
The company moved multiple assets from early to late-stage development, enhancing its pipeline maturity.
Regulatory applications for JACAfi XR, Opsilor for moderate AD, and povercinib for HS in Europe were submitted on time.
Revenues in the fourth quarter totaled $1.51 billion, up 28% versus the prior year, with full-year revenue reaching $5.14 billion, a 21% increase year over year.
The pediatric launch for Opsilor AD in the United States is off to a strong start, with sales annualizing around $30 million.

Negative

Despite growth, the company faces challenges in maintaining momentum in the competitive pharmaceutical market.
Price actions to expand formulary coverage may offset some of the expected sales growth for Opsalora.
The company anticipates most benefits from the moderate AD launch in Europe to materialize in 2027 and beyond, indicating a delay in realizing full potential.
The hematology and oncology business, while growing, still requires significant investment and focus to meet ambitious growth targets.
Incyte Corp (INCY) faces uncertainties and risks associated with regulatory approvals and market acceptance of new products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INCY.OQ - Incyte Corp
Q4 2025 Incyte Corp Earnings Call
Feb 10, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Insight 4th quarter in year-end 2025 financial results conference call and webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. You may be placed in the question queue at any time by pressing 1 on your telephone keypad, and we ask you to please limit yourselves to one question, then return to the queue. As a reminder, this conference is being recorded. If anyone should require operator assistance, please press 0. It's not my pleasure to turn the call over to your host, Alexis Smith, Vice President of Investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.